Sign in
BRVE Stock Price, Chart, Stats & News
Braveheart Bio, Inc.
Save
Braveheart Bio, Inc. (BRVE) does not currently pay a dividend.
1.95B
Market cap
–
Current P/E
–
Forward P/E
BRVE chart
1M
3M
1Y
5Y
Loading chart...
About
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Similar securities
Based on sector and market capitalization
Report issue